NCT01417143已完成2 期
Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 2
- 主要终点
- progression free survival
研究概览
简要总结
The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).
详细描述
open, uncontrolled, multi-center, phase II study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed adenoid cystic carcinoma
- •Local, locally advanced or metastatic disease documented as having shown progression on a scan (CT, MRI, MIBI scan) taken 2 to 12 months prior to baseline compared to a previous scan taken at any time in the past. Progression must be documented according to RECIST criteria.
- •Disease that is not amenable to surgery, radiation or combined modality therapy with curative intent and who is previously treated with chemotherapy or local treatment (e.g. transarterial chemoembolization)
- •Presence of at least one measurable target lesion for further evaluation according to RECIST criteria
- •18 years or older
- •ECOG performance status 0, 1
- •Previous treatment with chemotherapy, targeted agents, loco-regional therapy (e.g. chemoembolization) are permitted providing that toxicity has resolved to < or = grade 1 at study entry and that last treatment was at least 4 weeks prior to baseline assessment.
- •Adequate organ function
- •A patient with the willingness to comply with the study protocol during the study period and capable of complying with it
- •A patient who signed the informed consent prior to the participation of the study and who understands that he or she has a right to withdrawal from participation in the study at any time without any disadvantages.
排除标准
- •A patient with no measurable disease
- •Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to non-target lesions (within 2 weeks prior to study entry)
- •A patient with previous active or passive immunotherapy
- •A patient with intestinal obstruction or impending obstruction, recent active upper GI bleeding
- •A pregnant or lactating patient
- •A patient of childbearing potential without being tested for pregnancy at baseline or with being tested for positive. (A postmenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential)
- •A man or woman of childbearing potential who has no willingness to use a contraceptive measure during the study
- •A patient with history of another malignant disease within past 5 years, except curatively treated basal cell carcinoma of skin and cervical carcinoma in situ.
- •A patient with history of uncontrolled seizures, central nervous system disorder or psychiatric disorders that are considered clinically significant by the investigator that would prohibit the understanding of informed consent or that may be considered to interfere with the compliance of the administration of the study medications.
- •A patient with clinically significant heart disease (e.g. congestive heart failure, symptomatic coronary artery diseases, cardiac arrhythmia, etc) or myocardial infarction within past 12 months.
- •Ongoing cardiac arrhythmia of grade > or = 2, atrial fibrillation of any grade, or QTc interval > 450 msec for males or > 470 msec for female.
- •A patient with interstitial pneumonia or diffuse symptomatic fibrosis of the lungs
- •A patient with peripheral neuropathy of grade 1 by NCI CTC, caused by other factors (e.g. alcohol, diabetes, etc). If the absence of deep tendon reflexes is the only neurologic disorder, this condition does not apply to the exclusion criteria.
- •A patient with organ transplantation requiring immunosuppressive therapy
结局指标
主要结局
progression free survival
时间窗: 4 month
To determine 4month progression-free survival of TKI258 (Dovitinib) when administered as monotherapy in patients with unresectable adenoid cystic carcinoma
次要结局
- overall survival(2 years)
- response rate(8 weeks)
研究者
Yung-Jue Bang
professor
Seoul National University Hospital
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Study of Dovitinib (TKI258) in Adenoid Cystic CarcinomaAdenoid Cystic CarcinomaNCT01524692University of Virginia35
已完成
2 期
Dovitinib in Treating Patients With Recurrent or Progressive GlioblastomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain TumorNCT01753713Manmeet Ahluwalia, MD33
已完成
2 期
TKI258 for Metastatic Inflammatory Breast Cancer PatientsBreast CancerNCT01262027M.D. Anderson Cancer Center22
进行中（未招募）
1 期
PHASE II CLINICAL TRIAL OF DOVITINIB (TKI-258) IN FIRST-LINE METASTATIC OR LOCALLY ADVANCED NON-RESECTABLE ADRENOCORTICAL CARCINOMAEUCTR2011-002873-47-ESGrupo Español de Oncología Genitourinaria (SOGUG)
已完成
2 期
Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic CarcinomaRecurrent ACC, metastaticACC, Unreaectable ACCNCT02859012Seoul National University Hospital60